Carmen Alba-Linero

Prof. Carmen Alba-Linero


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2021 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
MRMarina Rodríguez-Calvo-de-Mora
Marina Rodríguez-Calvo-de-Mora
CDCayetano Domínguez‐Ruiz
Cayetano Domínguez‐Ruiz
FBFrancisco Barrero‐Sojo
Francisco Barrero‐Sojo
GRGustavo Rodríguez‐Moreno
Gustavo Rodríguez‐Moreno
CRCristina Antúnez Rodríguez
Cristina Antúnez Rodríguez
Carlos Rocha-de-LossadaCarlos Rocha-de-Lossada
Carlos Rocha-de-Lossada

1 November 2021 in Survey of Ophthalmology
Verified
Journal Article
Closed access
CACarmen Alba-Linero
Carmen Alba-Linero
EAEmilio Alba
Emilio Alba

11 November 2021 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
CACarmen Alba-Linero
Carmen Alba-Linero
Carlos Rocha-de-LossadaCarlos Rocha-de-Lossada
Carlos Rocha-de-Lossada
RRRahul Rachwani‐Anil
Rahul Rachwani‐Anil
MSMaite Sainz‐De‐La‐Maza
Maite Sainz‐De‐La‐Maza
GSGabriel Sena‐Corrales
Gabriel Sena‐Corrales
MRMarina Rodríguez-Calvo-de-Mora
Marina Rodríguez-Calvo-de-Mora

17 April 2019 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
CACarmen Alba-Linero
Carmen Alba-Linero
ASAnna Sala-Puigdollers
Anna Sala-Puigdollers
BRBarbara Romero
Barbara Romero
VLVictor Llorenç
Victor Llorenç
AAAlfredo Adan
Alfredo Adan
JZJavier Zarranz-Ventura
Javier Zarranz-Ventura
Purpose: To describe the long-term clinical outcomes in a cohort of uveitic eyes treated with the intravitreal dexamethasone implant (Ozurdex; Allergan, Inc). Methods: Seventy-nine (63 patients) receiving 134 implant injections over 82 months were included. Indication, visual acuity (VA), intraocular pressure (IOP), vitreous haze score (VHS), central retinal thickness (CRT), time to reinjection, systemic treatments, and complications data were recorded. Results: The cumulative probability of VA improvement was 80% at 1 month and 90% at 12 months, and it was maintained until 60 months. Eyes with baseline vitritis (VHS >0.5; 68%) had a probability of VHS improvement of 33% at 1 month, 75% at 12 months, and 85% at 60 months. The probability of CRT improvement was 33% at 1 month, 75% at 12 months, and 85% at 60 months. The most frequent adverse event was moderate IOP elevation (≥25 mmHg) in 30.3%, no cases of retinal detachment or endophthalmitis were observed. Conclusions: The dexamethasone implant provides favorable VA, CRT, and VHS long-term outcomes in uveitis with a reduced rate of severe adverse events.

26 October 2020 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
CACarmen Alba-Linero
Carmen Alba-Linero
JLJohn Paul Liscombe-Sepúlveda
John Paul Liscombe-Sepúlveda
VLVictor Llorenç
Victor Llorenç
JGJoan GiraltJosa
Joan GiraltJosa
AAAlfredo Adán
Alfredo Adán
To describe clinical findings through ultra-wide field (UWF) images and optical coherence tomography angiography (OCT-A), in Susac’s syndrome (SS). SS patients were retrospectively analyzed in a single center. Clinical features, ultra-wide-field retinographies (UWF-PR), UWF fluorescein angiographies (UWF-FA), and optical coherence tomography angiography & en face (OCT-A/EF) were reviewed. Twelve eyes from six patients with a mean follow-up of 35.66 months ± SD 36.88 were included. UWF-PR showed areas of retinal whitening and cotton-wool spots in all the eyes after acute attack. Segmentary mid peripheral arteriolitis could be observed in five eyes by UWF-FA in acute and convalescent stages. OCT-A revealed capillary density changes in all of the affected eyes. During the acute phase there was a well-preserved superficial capillary network, while deep retinal plexus showed a lower density in the affected areas. OCT-A/EF revealed deep retinal plexus drop-out and surrounding edematous retina in acute attacks, becoming atrophic over time. Conversely, superficial plexus was much less affected. Perifoveal reperfusion was seen in seven eyes after the acute attack. UWF-PR/FA and OCT-A/EF might be helpful to stablish an early diagnosis and to monitor SS progression.

30 July 2019 in Expert Review of Ophthalmology
Verified
Journal Article
Closed access
AAAlfredo Adan
Alfredo Adan
AMAina Moll-Udina
Aina Moll-Udina
CACarmen Alba-Linero
Carmen Alba-Linero
JFJuan Pablo Figueroa-Vercellino
Juan Pablo Figueroa-Vercellino
VLVictor Llorenç
Victor Llorenç
Introduction: Macular edema (ME) is defined as a thickening of the macular area, which results from a breakdown of the outer and/or inner blood-retina barrier. It is usually accompanied by quantity and quality loss of central vision. Uveitic macular edema (UME) is a leading cause of visual loss due to macular edema chronification. A number of treatment options are available for UME including periocular and intravitreal corticosteroids, immunosuppressants and biological agents. Pars plana vitrectomy also plays a role in refractory patients. Areas covered: We herein provide a summary of current options to treat UME, highlighting strengths and weaknesses on the basis of available literature and self-experience. Expert opinion: Visual prognosis in uveitis has improved as treatment of macular edema has done in the last decade. Corticosteroid slow-release intravitreal implants as well as anti-TNF and anti-IL-6 biologic drugs have been the cornerstone of these medical advances.